PDF(Pubmed)
Abstract：
During acute respiratory infections, women may concurrently receive human papillomavirus (HPV) and respiratory vaccines, as observed during the coronavirus disease 2019 (COVID-19) pandemic in China. However, few studies have assessed the safety of such concurrent administration, which could impact HPV vaccination schedules. This study analyzes the safety and optimal sequence of concurrent HPV and COVID-19 vaccinations. For this purpose, we surveyed women with both vaccines from January to October 2023 in Fujian Province, China. During this process, we collected vaccination history and adverse event (AE) data via telephone or interviews. Participants were grouped as Before, Concurrent, or After based on their vaccination sequence. A Chi-squared test, exact Fisher tests, and logistic regression were used to analyze the incidence of AEs and factors influencing vaccine safety. Overall, 1416 eligible participants were included. Although overall AE risk with the HPV vaccine was unaffected by vaccination sequence, individual AEs varied statistically between groups, including pain at the vaccination site (p < 0.001) and prolonged menstruation duration (p = 0.003). Based on the results, the optimal sequence would be to receive the HPV vaccine after the COVID-19 vaccine (After group). This insight may guide future emergency vaccination sequences for HPV and other respiratory infectious diseases.
摘要：
在急性呼吸道感染期间，女性可以同时接受人乳头瘤病毒（HPV）和呼吸道疫苗，正如在中国2019年冠状病毒病(COVID-19)大流行期间观察到的那样。然而,很少有研究评估这种同时给药的安全性，这可能会影响HPV疫苗接种计划。本研究分析了同时接种HPV和COVID-19疫苗的安全性和最佳顺序。为此,我们调查了福建省2023年1月至10月接种两种疫苗的女性，中国。在这个过程中,我们通过电话或访谈收集了疫苗接种史和不良事件(AE)数据.参与者被分组为之前，并发,或之后基于他们的疫苗接种顺序。卡方检验，精确的Fisher检验,采用logistic回归分析AEs的发生率及影响疫苗安全性的因素。总的来说,1416名符合条件的参与者被包括在内。尽管HPV疫苗的总体AE风险不受疫苗接种顺序的影响，个体AE在组间有统计学差异，包括疫苗接种部位疼痛（p<0.001）和月经持续时间延长（p=0.003）。根据结果,最佳顺序是在COVID-19疫苗接种后接种HPV疫苗(后组)。这种见解可以指导未来HPV和其他呼吸道传染病的紧急疫苗接种顺序。
